Chicago Bears cornerback Jaylon Johnson will be placed on injured reserve this week, a new report says.
Johnson, who was already ruled out for Sunday’s game against the Dallas Cowboys with a groin injury, will miss a minimum of four games because of that designation, according to NFL Network’s Ian Rapoport.
Johnson had missed all of training camp with a groin injury he suffered in offseason workouts, and had been out for the team’s first game against the Minnesota Vikings.
While Johnson was able to practice prior to the team’s loss to the Detroit Lions, he left that game in the second quarter with another groin injury, and now he’ll miss a minimum of four games, though it’s unclear when he will return to the field.
Johnson has appeared in 71 career games with the Bears, registering seven interceptions and one touchdown in his NFL career. He had two interceptions and eight passes defended last season, and was named to the Pro Bowl for the second straight year.
A corresponding roster move has not yet been made by the Bears, who are set to take on the Dallas Cowboys Sunday at 3:25 p.m.
This story uses functionality that may not work in our app. Click here to open the story in your web browser.
Hence then, the article about chicago bears roster moves jaylon johnson headed to ir was published today ( ) and is available on NBC Chicago ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Chicago Bears roster moves: Jaylon Johnson headed to IR )
Also on site :
- Ukraine-Russia war latest: Zelensky awaits Putin response to new peace plan while Christmas Eve blast kills 3 in Moscow
- JCPenney Has a 'Stunning' White Sapphire Jewelry Set on Sale for Just $16, and It's Perfect for Every Occasion
- China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval